Compare HBCP & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HBCP | PRTC |
|---|---|---|
| Founded | 1908 | 2015 |
| Country | United States | United States |
| Employees | 481 | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.8M | 464.3M |
| IPO Year | 2008 | N/A |
| Metric | HBCP | PRTC |
|---|---|---|
| Price | $63.14 | $18.15 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $63.50 | N/A |
| AVG Volume (30 Days) | ★ 23.0K | 2.9K |
| Earning Date | 01-26-2026 | 08-28-2025 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | ★ 24.56 | N/A |
| EPS | ★ 5.62 | 0.20 |
| Revenue | ★ $145,087,000.00 | $6,391,000.00 |
| Revenue This Year | $2.60 | N/A |
| Revenue Next Year | $3.27 | N/A |
| P/E Ratio | $11.28 | ★ $8.57 |
| Revenue Growth | 11.42 | ★ 1265.60 |
| 52 Week Low | $39.59 | $13.30 |
| 52 Week High | $63.67 | $20.00 |
| Indicator | HBCP | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 65.98 | 52.17 |
| Support Level | $59.54 | $17.31 |
| Resistance Level | $62.02 | $18.82 |
| Average True Range (ATR) | 1.45 | 0.66 |
| MACD | 0.31 | 0.02 |
| Stochastic Oscillator | 82.79 | 34.47 |
Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities. The principal sources of funds are customer deposits, repayments of loans, repayments of investments and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.